Synaffix Expands ADC Licensing Partnerships with Boehringer Ingelheim and Mitsubishi Tanabe

Synaffix Partnerships:
Synaffix has entered into licensing agreements with Boehringer Ingelheim and Mitsubishi Tanabe to utilize its antibody-drug conjugate (ADC) technology for cancer treatment13.

Boehringer Ingelheim Deal:
The agreement with Boehringer Ingelheim includes an upfront payment and potential milestone payments up to $1.3 billion, plus royalties on net sales of resulting products1.

Mitsubishi Tanabe Partnership:
Synaffix has also licensed its ADC technology to Mitsubishi Tanabe, further expanding its partnerships in the ADC space3.

ADC Technology:
Synaffix's ADC technology uses enzymatic modification of native glycan anchor points on antibodies, enabling the development of enhanced ADCs or bispecifics1.

Oncology Portfolio:
The partnership with Boehringer Ingelheim aims to develop advanced ADCs for cancer treatment, combining antibodies' targeting ability with potent cancer-killing drugs for precise delivery to cancer cells1.

Previous Partnerships:
Synaffix has previously entered into significant licensing agreements, including a $2 billion deal with Amgen in 20234.

Sources:

1. https://www.stocktitan.net/news/LZAGY/boehringer-ingelheim-broadens-oncology-portfolio-with-license-for-c5uk2zzwd2go.html

3. https://www.thepharmaletter.com/brief-synaffix-licenses-adc-technology-to-mitsubishi-tanabe

4. https://synaffix.com/synaffix-enters-license-agreement-with-amgen-to-build-next-generation-adcs/